Quick Answer
Vaxcyte, Inc. reported Net Income Loss of -$766.63 million for the year ending 2025.
- Vaxcyte, Inc. showed a decrease of -65.2% in Net Income Loss from 2024 to 2025.
- This data is from Vaxcyte, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$13.67 million | Q2 2019: -$10.67 million | Q3 2019: -$11.32 million | Q4 2019: -$14.62 million | Q1 2020: -$27.14 million | Q2 2020: -$20.32 million | Q3 2020: -$21.02 million | Q4 2020: -$20.74 million | Q1 2021: -$21.22 million | Q2 2021: -$23.68 million | Q3 2021: -$26.62 million | Q1 2022: -$38.99 million | Q2 2022: -$48.53 million | Q3 2022: -$57.92 million | Q1 2023: -$60.46 million | Q2 2023: -$68.34 million | Q3 2023: -$92.66 million | Q1 2024: -$95.02 million | Q2 2024: -$128.70 million | Q3 2024: -$103.12 million | Q1 2025: -$140.72 million | Q2 2025: -$166.57 million | Q3 2025: -$212.83 million.
- Over the full 8 years of available data (2018 to 2025), Vaxcyte, Inc.'s Net Income Loss has declined by 2,500.1%.
- Historical annual values: Fiscal year 2025: -$766.63 million | Fiscal year 2024: -$463.93 million | Fiscal year 2023: -$402.27 million | Fiscal year 2022: -$223.49 million | Fiscal year 2021: -$100.08 million | Fiscal year 2020: -$89.22 million | Fiscal year 2019: -$50.27 million | Fiscal year 2018: -$29.49 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: